Tendinopathy Global Prevalence and Trends

How Common Is Tendinopathy Worldwide?

Tendinopathy is one of the most prevalent musculoskeletal disorders encountered in both primary care and sports medicine. Population-level estimates suggest it accounts for approximately 30 percent of all musculoskeletal primary care consultations, though exact figures vary by country, diagnostic criteria, and clinical setting. [1]

The condition is not confined to athletes. Office workers, manual laborers, older adults, and people with metabolic conditions such as type 2 diabetes each carry distinct risk profiles. A 2021 systematic review published in the British Journal of Sports Medicine found that tendinopathy prevalence varies widely across studies, partly because there is no universally agreed diagnostic gold standard, with clinical diagnosis, ultrasound, and MRI producing different prevalence estimates for the same population. [2]

Why Prevalence Estimates Differ So Much

Diagnostic heterogeneity is the main driver of variability. Studies relying on self-reported pain produce higher prevalence figures than those requiring imaging confirmation. A population-based cohort study from the Netherlands found a 12-month incidence of Achilles tendinopathy of 2.35 per 1,000 person-years in the general population, rising to 10 per 1,000 person-years in recreational runners. [3]

Global Consultation Burden

In the United Kingdom, the National Health Service records approximately 85,000 new Achilles tendinopathy diagnoses per year, with lateral elbow tendinopathy (tennis elbow) generating an estimated 1.3 million physician visits annually in the United States alone. [4] These figures almost certainly undercount total burden because many individuals manage symptoms without seeking formal care.

Achilles Tendinopathy: Prevalence by Population

Achilles tendinopathy is the most extensively studied tendon disorder in the epidemiological literature. The lifetime risk for recreational runners reaches 52 percent in some cohort analyses, making it the leading cause of running-related injury requiring medical attention. [3]

General Population Rates

In a large Dutch primary-care database study (N=134,000 registered patients), the annual incidence of Achilles tendinopathy was 2.35 per 1,000 person-years overall. [3] Men were affected 2 to 3 times more often than women in this age-adjusted analysis, a finding consistent across multiple European cohort datasets.

Athlete-Specific Incidence

Among elite track and field athletes, point prevalence reaches 9 to 18 percent depending on discipline and training load. [5] A prospective study following Norwegian elite athletes found that 11.8 percent reported active Achilles tendinopathy at any given time during a competitive season. Insertional and mid-portion subtypes carry different biomechanical profiles but are roughly equally represented in clinical series. [5]

Recurrence and Chronicity

Recurrence is a defining feature of this condition. Up to 44 percent of patients who achieve symptomatic resolution will experience a recurrence within five years, particularly without a structured progressive loading program. [6] Chronic Achilles tendinopathy, defined as symptoms persisting beyond three months, accounts for the majority of cases seen in specialist tendon clinics.

Rotator Cuff Tendinopathy: Shoulder Burden Across the Lifespan

Rotator cuff tendinopathy and related shoulder pain syndromes collectively represent the third most common musculoskeletal disorder in primary care after low back pain and knee osteoarthritis. [7]

Imaging Prevalence vs. Symptomatic Prevalence

Imaging studies consistently reveal a gap between structural pathology and reported symptoms. A systematic review in JAMA examined cadaveric and ultrasound studies and found full-thickness rotator cuff tears in 22.1 percent of the general population, with partial-thickness tears and tendinopathic change present in up to 34 percent of adults over age 60 who reported no significant shoulder pain. [8]

Symptomatic rotator cuff tendinopathy has a point prevalence of 7 to 26 percent in working-age adults depending on occupational exposure. [9] Overhead workers, including painters, electricians, and warehouse staff, sit at the higher end of that range.

Age and Sex Distribution

Prevalence rises sharply after age 40. In population surveys from Sweden and the United States, approximately 54 percent of adults over 70 have imaging evidence of rotator cuff pathology, whether symptomatic or not. [8] Women over 60 are more likely to present with symptomatic rotator cuff tendinopathy than age-matched men, a reversal of the male predominance seen in Achilles tendon disease.

Lateral Elbow Tendinopathy (Tennis Elbow): Occupational and General Population Data

Lateral epicondylitis, or lateral elbow tendinopathy, carries a general-population point prevalence of 1 to 3 percent and is strongly tied to occupational exposure. [10]

Peak Age and Sex

The condition peaks between ages 40 and 50 and affects men and women at roughly equal rates, though some occupational cohorts show slight female predominance due to task allocation patterns in manufacturing and assembly work. [10]

Occupational Risk Amplification

Workers performing repetitive forearm rotation or gripping tasks for more than two hours per day carry approximately twice the incidence risk of the general population. [11] A European surveillance study found lateral epicondylitis among the top five compensated occupational musculoskeletal disorders in the Netherlands, Belgium, and France. The condition also generates significant presenteeism costs: affected workers lose an average of 13.8 workdays per episode in US-based disability analyses. [12]

Spontaneous Resolution and Recurrence

Many textbooks describe tennis elbow as self-limiting, and roughly 80 to 90 percent of patients do recover within 12 months with conservative care. [13] Recurrence rates of 8 to 26 percent are reported in cohort studies extending beyond two years, with higher recurrence tied to continued occupational exposure without ergonomic modification.

Patellar Tendinopathy: The Athlete's Overuse Condition

Patellar tendinopathy (jumper's knee) carries the highest prevalence in sports that demand repetitive jumping and landing. Point prevalence reaches 45 percent in elite volleyball players and 32 percent in elite basketball players. [14]

General vs. Elite Athlete Prevalence

Outside elite sport, patellar tendinopathy is less common but not rare. Cross-sectional surveys of recreational athletes find prevalence figures of 8 to 15 percent in those training three or more times per week in court sports. [14] In the general non-athletic adult population, imaging-confirmed patellar tendinopathy is present in approximately 2 to 5 percent, most of it asymptomatic. [15]

Bilateral Presentation

Bilateral patellar tendinopathy is documented in 20 to 30 percent of cases in volleyball studies, complicating management because relative rest from jumping is difficult to achieve symmetrically. [14] The Oslo Sports Trauma Research Center has tracked this condition prospectively in Norwegian elite athletes since 2003, providing some of the most reliable longitudinal prevalence data available. [15]

Metabolic and Systemic Drivers of Rising Tendinopathy Rates

Tendinopathy prevalence is climbing not only because of growing athletic participation and aging demographics, but also because of expanding metabolic disease burden. [16]

Diabetes and Tendon Pathology

Type 2 diabetes is an independent risk factor for tendinopathy across multiple tendon sites. Advanced glycation end-products accumulate in collagen-rich tissues and impair tenocyte function and tendon mechanical properties. A systematic review and meta-analysis published in PLOS ONE (N=12 studies) found that people with diabetes had a 3.6-fold higher odds of Achilles tendinopathy compared with normoglycemic controls (OR 3.6, 95% CI 2.1 to 6.1). [16]

Obesity and Mechanical Load

Elevated BMI increases compressive and tensile loads on lower-limb tendons. The same metabolic milieu, characterized by elevated circulating lipids, insulin resistance, and low-grade systemic inflammation, also impairs tendon matrix remodeling at a cellular level. [17] Population studies from Australia and the United Kingdom find that adults with a BMI above 30 kg/m2 are approximately 1.7 times more likely to present with symptomatic Achilles or patellar tendinopathy than normal-weight peers. [17]

Fluoroquinolone-Associated Tendinopathy

Drug-induced tendinopathy deserves specific mention. The US Food and Drug Administration issued a black-box warning in 2008 for fluoroquinolone antibiotics (ciprofloxacin, levofloxacin, and related agents) due to risk of tendinitis and tendon rupture, with Achilles tendon most commonly affected. [18] The FDA strengthened this warning in 2016, noting that the risk of Achilles tendon rupture is 3.2 times higher in fluoroquinolone users than in matched non-users, and even higher in patients over 60 or on concurrent corticosteroid therapy. [18]

Age-Related Trends and the Degenerative Pathway

Tendinopathy follows a recognizable age-related trajectory. Below age 30, acute inflammatory presentations and acute-on-chronic overuse injuries predominate. Between ages 40 and 60, degenerative tendinopathy, characterized histologically by disorganized collagen, increased ground substance, and neovascularization without classical inflammation, becomes the dominant phenotype. [19]

Histological Shift With Age

Tendon biopsy studies show that tenocyte density and collagen fibril diameter both decline after the fourth decade, reducing tensile strength and increasing susceptibility to load-induced micro-damage. [19] This partly explains why master athletes (age 35 and older) experience disproportionately high rates of tendinopathy relative to younger counterparts training at equivalent loads.

Population Aging as a Trend Driver

Global population aging is projected to increase the number of adults over 60 from 1 billion in 2020 to 2.1 billion by 2050, according to World Health Organization projections. [20] Because degenerative tendinopathy prevalence rises sharply after age 60, this demographic shift alone is expected to substantially increase total tendinopathy case numbers over the coming three decades, independent of any change in physical activity patterns.

Sex Differences and Hormonal Influences on Prevalence

Sex-based differences in tendinopathy prevalence are site-specific and influenced by hormonal, anatomical, and occupational variables. [21]

Estrogen and Tendon Properties

Estrogen receptors are present on tenocytes, and estrogen influences collagen synthesis and mechanical stiffness. Observational data suggest that postmenopausal women experience accelerated tendon property decline compared with premenopausal women of similar age, which may partly explain the rising rotator cuff tendinopathy burden in women over 60. [21] The clinical implications of hormone therapy on tendon health remain an active area of research, with small randomized trials suggesting that estrogen supplementation may slow tendon stiffness loss in postmenopausal women.

Male Predominance in Achilles and Patellar Sites

Men carry higher Achilles and patellar tendinopathy rates across nearly all studied populations, likely reflecting higher total tendon loading through sport and occupational activity, combined with differences in calf muscle architecture and biomechanics. [3]

Geographic and Socioeconomic Variation

High-income countries generate the majority of published tendinopathy epidemiology, creating a systematic gap in global data. [22]

Underreporting in Low- and Middle-Income Countries

Africa, South and Southeast Asia, and Latin America are substantially underrepresented in peer-reviewed tendinopathy cohort studies. Where data exist, occupational tendinopathy in agricultural and manufacturing workers carries high prevalence, but healthcare access limitations mean many cases go undiagnosed and unrecorded. [22] A 2020 global burden of disease analysis estimated that musculoskeletal disorders, including tendinopathies, produced 149 million years lived with disability (YLD) worldwide in 2019, with the largest absolute YLD counts in South Asia and East Asia due to population size. [23]

Emerging Data From Asia

A cross-sectional study of Chinese factory workers found a 12-month prevalence of upper-limb tendinopathy (primarily lateral epicondylitis and de Quervain tenosynovitis) of 18.4 percent in workers performing repetitive assembly tasks. [24] This figure aligns with European occupational cohort data and suggests that occupational tendinopathy burden in middle-income manufacturing economies is substantial but poorly captured in global prevalence estimates.

Current Guideline Framing of the Epidemiological Problem

The British Journal of Sports Medicine's 2019 clinical commentary on tendinopathy management states: "The evidence base now clearly supports a load-management framework as the primary therapeutic and preventive tool, given the high prevalence and recurrence rates documented across all major tendon sites." [25] This statement reflects a shift away from inflammation-centered models and toward mechanobiology, a shift that the epidemiological burden data helped drive.

The American Academy of Orthopaedic Surgeons (AAOS) does not yet have a dedicated tendinopathy clinical practice guideline, but its shoulder pain and rotator cuff guidelines acknowledge that asymptomatic tendinopathy on imaging is highly prevalent and that imaging findings alone should not drive treatment decisions. [26]

A 2023 consensus statement from the International Scientific Tendinopathy Symposium Consortium (ISTSC) recommended standardizing prevalence reporting by requiring both imaging and clinical criteria for diagnosis in future epidemiological studies, citing the current wide confidence intervals as a barrier to policy development. [27]

Risk Factor Summary and Clinical Implications

Age, sex, occupational loading, sport participation, metabolic disease, and drug exposure each contribute independently to tendinopathy risk. [28]

Modifiable vs. Non-Modifiable Factors

Non-modifiable risk factors include age, sex, prior tendon injury history, and genetic collagen variants. Modifiable factors include training load, BMI, glycemic control, fluoroquinolone use, and ergonomic design of workstations. [28] Targeting modifiable factors is the basis of all current prevention strategies, and population-level interventions focusing on workplace ergonomics and metabolic health management hold the greatest potential for reducing total tendinopathy burden.

Screening Implications

Given the high prevalence of asymptomatic imaging findings, routine tendon imaging in asymptomatic individuals is not supported by current evidence. A targeted history and physical examination remain the recommended first-line assessment approach in both primary care and specialist settings. [29] The Victorian Institute of Sport Assessment (VISA) questionnaire family (VISA-A for Achilles, VISA-P for patellar tendon) provides validated, reproducible outcome measures that also serve as screening tools in high-risk athletic populations. [29]

People with type 2 diabetes or a history of fluoroquinolone use present with Achilles tendinopathy at a mean age approximately 8 years earlier than metabolically healthy patients, suggesting that metabolic risk screening warrants integration into tendon health assessments. [16]